Articles related to Oncology, Surgical

In a phase 3 trial comparing belzutifan to everolimus for advanced renal-cell carcinoma, belzutifan demonstrated a significant improvement in progression-free survival at 18 months (24.0% vs. 8.3%, P=0.002) and objective response rate (21.9% vs. 3.5%, P<0.001).

Financial pressures and staffing shortages are creating a challenging environment for oncology care, particularly in community hospitals.

New data suggests that the Galleri blood test’s sensitivity for early-stage cancers may be lower than initially reported, potentially limiting its utility as a screening tool.

Prostate cancer screening guidelines that use race as a criterion are under ethical scrutiny, with experts calling for a shift towards universal, unbiased risk assessment that addresses socioeconomic factors and healthcare access disparities.

The annual cost of cancer screening represents a notable portion of overall U.S. health care system costs related to cancer, with private insurance covering the majority of expenses.

Afamitresgene autoleucel offers a novel approach to treating metastatic synovial sarcoma, with an overall response rate of 43.2% in clinical trials, providing a much-needed alternative to traditional chemotherapy.